ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Integrative transcriptomic and structural modeling reveal CASP1, TLR3, PYCARD, and CD274 as immune-modulatory drivers in breast cancer.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BRCA) remains one of the most prevalent malignancies worldwide, characterized by marked molecular heterogeneity and diverse clinical outcomes. Necroptosis and ferroptosis, two regulated forms of programmed cell death (PCD), play pivotal roles in tumor progression and immune regulation; however, their combined influence on BRCA pathogenesis remains inadequately understood. To elucidate these interactions, transcriptomic datasets (GSE254218, GSE220608) were integrated to identify differentially expressed genes (DEGs) using edgeR (|log2FC|> 1, FDR < 0.05). From 805 DEGs, intersection with 614 necroptosis-related genes (NRGs) and 259 ferroptosis-related genes (FRGs) yielded 37 candidate cell death-related genes (CDRGs). CytoHubba analysis prioritized 25 hub genes, and UALCAN expression profiling identified six significantly stage-associated genes CASP1, TLR3, PYCARD, KRT5, MAP1B, and MMP13 (p < 1E - 12). Functional enrichment (GO/KEGG) and protein-protein interaction (PPI) analyses linked these genes to immune activation, inflammatory signaling, and PCD-associated pathways. Integrated survival and immune infiltration analyses (CIBERSORT, TIMER 2.0) highlighted CASP1, TLR3, PYCARD, and CD274 as key prognostic biomarkers modulating the BRCA tumor microenvironment. To evaluate genetic and structural perturbations affecting these targets, deleterious nonsynonymous SNPs (nsSNPs) were filtered using SIFT, PolyPhen-2, CADD, REVEL, MetaLR, and Mutation Assessor. Structural characterization identified nine high-impact nsSNPs (ΔΔG < - 1.7 kcal/mol), particularly in TLR3 (L104N, L381P, L77P) and CD274 (W57S, C155S, G159D, Y112N), indicating potential disruption of receptor stability, immune checkpoint interactions, and inflammasome regulation. This integrative multi-omics and structural pharmacogenomics framework reveals a robust four-gene signature (CASP1, TLR3, PYCARD, CD274) that links necroptosis, ferroptosis, and immune modulation in BRCA, providing promising avenues for precision oncology and therapeutic target development.
Indexed as
Identifiers
41549178What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.